Clinical Study
RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution
Table 3
Disease status before 90Y-IT therapy.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NHL-F: Non-Hodgkin follicular lymphoma; CR: complete response; PR: partial response; NR: no response; NV: non valuable. |